Oncotelic Therapeutics Featured in BioMedWire Editorial on Drug-Delivery Market Growth

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced its inclusion in a BioMedWire editorial that examines the growing investor interest in platform biotech companies as the global drug-delivery market approaches an estimated $410 billion opportunity. The editorial underscores the industry's focus on overcoming challenges such as drug penetration, tumor targeting, therapeutic resistance, and maintaining consistent intratumoral exposure. Oncotelic's Sapu003 and Deciparticle platforms are highlighted as examples of nanotechnology-driven drug-delivery approaches designed to enhance the clinical utility of existing therapies through improved pharmacokinetics and delivery performance.

The drug-delivery market's projected growth reflects increasing demand for advanced delivery systems that can improve the efficacy and safety of therapeutics. Oncotelic's platforms aim to address key limitations in current treatments by leveraging nanotechnology to optimize drug distribution and targeting. The Sapu003 platform, in particular, is designed to enhance the delivery of chemotherapeutic agents, potentially reducing side effects and improving patient outcomes. The Deciparticle platform focuses on overcoming biological barriers to drug delivery, such as the blood-brain barrier, which is critical for treating central nervous system malignancies.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company's pipeline includes directly owned and developed drug candidates, as well as those advanced through strategic partnerships. Oncotelic benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The company also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.

Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens its position in oncology and rare disease therapeutics. The editorial notes that Oncotelic's approach aligns with broader industry trends toward platform-based technologies that can be applied across multiple therapeutic areas, offering potential for scalability and efficiency in drug development.

The full press release is available at https://ibn.fm/laaQ6. For more information about Oncotelic, visit the company's newsroom at https://ibn.fm/OTLC.